Replies to post #290353 on Avid Bioservices Inc (CDMO)

[asmarterwookie]

"the early stage of product development"

Who is developing it?

Peregrine is ONLY doing up to POC.

"Product Development" is another wheelhouse.

IMHO

wook

[Protector]

av428, your are mixing up things.

PPHM's proof of concept program is in early stage, they released one results and they will need one per market they address. However the first one was BINGO right away because testing in Ovarian, as the PR explained, was a market with a need and PPHM's exosome test had 100% accuracy.

For a partner, that alone, is sufficient. They may close a SMALL partnership and provide mile-stones for the other cancers. Such initial partnership would do it for us.

Furthermore PPHM is developing proof of concepts that will also show the OTHER characteristics of the Exosome blood test. I am not aiming at the CHEAP, FAST and SIMPLE because that a partner can asses based on the first test, as they are all the same but just looking for different molecules depending on the cancer. I am speaking about the the Exosome test properties.

Said 100-200Bil$ market is only for those tests that do them all. And PPHM's test is the ONLY that does.

Furthermore I think that if something would happen tomorrow it would need an UP-FRONT PR of something that will be said during the Q/CC in the evening.

But those that think that only a partnership does the trick for Wall Street, think again. As an example, without that example being a limiting list, the announcement of the HALO/ROCHE production is a money maker. Bringing profitability 3 or 6 months closer (would be kind of End of CALENDAR YEAR), would certainly also not go unnoticed if it is accompanied by a good Avid quarter that full-fills the expectations.

What if the Ronin 13-D and then 13-G filing containing the "wanting to talk to the BoD" were ALREADY a fact. Think, would Roning invest about 25Mil shares in PPHM, clearly being a LONG TERM investment firm with only 4 stocks in portfolio and a tradition of PARTICIPATING (by sitting on the board) in companies start investing IF they didn't UP-FRONT know that they have a chance to have a board seat?

Buy, talk to PPHM, get a NO, then Sell? NO, that is mostly NOT how they do it. Certainly not with a company that has a Poison Pill installed, a Bod that Guards it, and Delaware bylaws that almost give the BoD a license to kill and get away with it? NO WAY. Stafford III knows at this moment if a BoD seat at PPHM is a possibility or totally excluded. With only 4 stocks in portfolio they have all the time to prepare this, hear around, do some informal talks, etc and then work within an EDUCATED frame work.

So what if PPHM announces an extra BoD member that already invested in 25Mil shares, or two BoD member if maybe Dart also wants in, he has MORE then 25Mil shares.

From jakedogman's post:

Stafford (Ronin) was on BOD at Xencor up until Jan 2016 and still owns 7 mil shares...

Xencor has partnerships with the following...

Alexion
CSL-Janssen
Boehringer Ingelheim
Janssen
Merck
Amgen
Novartis

All of them are on the hunt ....